LENZ Therapeutics (LENZ) Q2 FY26 earnings call

LENZ Therapeutics reported continued, albeit modest, growth in Q2 FY26, with significant acceleration in July scripts driven by the launch of telehealth and a national TV campaign. The company highlighted encouraging patient persistence in its e-pharmacy channel, with over 60% of patients purchasing multiple packs and mature cohorts tracking towards five annual packs. Management is now focused on optimizing commercial investments based on performance data to drive sustained patient growth and expand its global presence.